Key points are not available for this paper at this time.
The second revision of international staging system (R2‐ISS) shows promise in patients with multiple myeloma treated with a regimen of novel agent‐based induction therapy, autologous stem cell transplant and maintenance therapy, but challenges persist. This study by Alzahrani et al. underscores the importance of refining risk assessment tools for tailored treatment strategies. Commentary on: Alzahrani et al. Impact of revised international staging system 2 (R2‐ISS) risk stratification on outcomes of patients with multiple myeloma receiving autologous hematopoietic stem cell transplantation. Br J Haematol 2024;204:1944‐1952.
Mohan et al. (Sun,) studied this question.